NEW YORK (GenomeWeb News) – The Biotechnology and Biological Science Research Council said today that it has provided £10 million ($16.1 million) to launch an investment fund that will fund early-stage companies in the UK that are focused on commercializing synthetic biology technologies.

The BBSRC said the private investment company Midven will manage the fund, which will provide investments, strategic support, and help startup companies leverage private capital. Midven's Rainbow Seed Fund specializes in supporting firms that spin out from publicly-funded research programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."